Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.

Gilead Sciences and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to sustained suppression of the virus out to 48 weeks in a ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from ... and lenacapavir, a first-in-class HIV-1 capsid inhibitor. These late-breaking data were presented during an oral session ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE ... of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the ...

There is currently no cure for HIV or AIDS. About Islatravir (MK-8591) and Merck’s HIV Research Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

(RTTNews) - Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK ... a first-in-class HIV-1 capsid inhibitor. At 48 weeks, the novel investigational combination maintained a high rate of viral ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Data indicate that HIV-1 RNA and CD4 cell counts do not remain stable indefinitely (despite some marginal benefits for blunted and slightly elevated CD4 cell counts); therefore, leaving a ...

The data was presented at the ID Week 2024. At 48 weeks, the investigational combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically ...